Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
IMUC: Immunotherapy On Multiple Fronts
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
Cancer Vaccines: Investing Opportunities Beyond Dendreon
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
Dendreon to Build $70 Million Plant Near Atlanta
The 160,000 square-foot facility could bring at least 300 jobs to Georgia.